Clin Mol Hepatol > Volume 29(4); 2023 > Article |
|
Values are presented as median (interquartile range) or number (%).
CHB, chronic hepatitis B viral infection; INR, international normalized ratio; IU, international unit; APRI, aspar tate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index; MELD, model for end-stage liver disease; HBeAg, hepatitis B e antigen; REACH-B, risk estimate for hepatocellular carcinoma in chronic hepatitis B.
Characteristic |
Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Sex (female) | 0.46 | 0.31–0.69 | <0.001 | 0.57 | 0.38–0.87 | 0.010† |
Age (per 1 year) | 1.03 | 1.01–1.05 | 0.001 | 1.02 | 1.01–1.04 | 0.015† |
Body mass index (kg/m2) | 1.04 | 0.99–1.08 | 0.108 | |||
Antiviral therapy (yes) | 1.46 | 1.05–2.03 | 0.024 | 0.95 | 0.65–1.38 | 0.785 |
HBeAg (positive) | 1.16 | 0.79–1.70 | 0.458 | |||
Alanine aminotransferase (IU/L) | 1.00 | 0.99–1.01 | 0.518 | |||
Albumin (g/L) | 0.63 | 0.50–0.80 | <0.001 | 0.77 | 0.59–1.02 | 0.068 |
Total bilirubin (mg/dL) | 1.01 | 0.90–1.12 | 0.912 | |||
PT-INR | 1.00 | 0.94–1.07 | 0.982 | |||
Platelet count (K/mm3) | 0.99 | 0.99–0.99 | <0.001 | 0.99 | 0.99–0.99 | 0.002† |
AFP (ng/mL) | 1.00 | 0.99–1.01 | 0.157 | |||
Standardized liver volume (mL/m2) | 0.99 | 0.99–1.00 | 0.099 | |||
Standardized spleen volume ≥112.6 mL/m2 | 1.92 | 1.36–2.69 | <0.001 | 1.71 | 1.21–2.42 | 0.002† |
Skeletal muscle index (cm2/m2) | 1.00 | 0.99–1.01 | 0.901 | |||
Visceral adipose tissue index (cm2/m2) | 1.00 | 0.99–1.01 | 0.709 | |||
Subcutaneous adipose tissue index (cm2/m2) | 0.99 | 0.99–1.00 | 0.016 | 1.00 | 0.99–1.01 | 0.835 |
APRI | 1.00 | 0.97–1.03 | 0.982 | |||
FIB-4 | 1.00 | 0.99–1.01 | 0.923 | |||
REACH-B | 1.26 | 1.20–1.33 | <0.001 | 1.20 | 1.12–1.28 | <0.001† |
MELD | 1.07 | 1.02–1.12 | 0.003 | 1.00 | 0.95–1.06 | 0.895 |
CHB, chronic hepatitis B viral infection; HCC, hepatocellular carcinoma; CI, confidence interval; HBeAg, hepatitis B e antigen; PT-INR, prothrombin time international normalized ratio; AFP, alpha fetoprotein; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index; REACH-B, risk estimate for hepatocellular carcinoma in chronic hepatitis B; MELD, model for end-stage liver disease.
Characteristic |
Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Sex (female) | 1.09 | 0.75–1.60 | 0.647 | |||
Age (per 1 year) | 1.06 | 1.04–1.08 | <0.001 | 1.06 | 1.04–1.08 | <0.001† |
Body mass index (kg/m2) | 1.01 | 0.98–1.05 | 0.493 | |||
Antiviral therapy (yes) | 1.14 | 0.79–1.66 | 0.488 | |||
HBeAg (positive) | 1.21 | 0.78–1.88 | 0.397 | |||
Alanine aminotransferase (IU/L) | 1.00 | 0.99–1.01 | 0.369 | |||
Albumin (g/L) | 0.52 | 0.42–0.64 | <0.001 | 0.59 | 0.45–0.77 | <0.001† |
Total bilirubin (mg/dL) | 0.91 | 0.69–1.19 | 0.469 | |||
PT-INR | 1.00 | 0.91–1.10 | 0.967 | |||
Platelet count (K/mm3) | 1.00 | 0.99–1.01 | 0.115 | |||
AFP (ng/mL) | 1.00 | 0.99–1.01 | 0.245 | |||
Standardized liver volume (mL/m2) | 1.00 | 0.99–1.00 | 0.383 | |||
Standardized spleen volume ≥145.7 mL/m2 | 2.14 | 1.39–3.27 | <0.001 | 2.34 | 1.51–3.63 | <0.001† |
Skeletal muscle index (cm2/m2) | 1.00 | 0.99–1.01 | 0.780 | |||
Visceral adipose tissue index ≥22.65 cm2/m2 | 0.61 | 0.41–0.90 | 0.013 | 0.57 | 0.38–0.84 | 0.005† |
Subcutaneous adipose tissue index (cm2/m2) | 0.99 | 0.99–1.00 | 0.120 | |||
APRI | 0.99 | 0.92–1.05 | 0.660 | |||
FIB-4 | 1.00 | 0.98–1.01 | 0.855 | |||
REACH-B | 1.14 | 1.07–1.21 | <0.001 | 1.05 | 0.98–1.12 | 0.144 |
MELD | 1.07 | 1.02–1.12 | 0.008 | 1.02 | 0.96–1.07 | 0.564 |
CHB, chronic hepatitis B viral infection; CI, confidence interval; HBeAg, hepatitis B e antigen; PT-INR, prothrombin time international normalized ratio; AFP, alpha fetoprotein; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index; REACH-B, risk estimate for hepatocellular carcinoma in chronic hepatitis B; MELD, model for end-stage liver disease.
Characteristic |
Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Sex (female) | 0.70 | 0.57–0.85 | <0.001 | 0.73 | 0.56–0.95 | 0.017† |
Age (per 1 year) | 1.04 | 1.03–1.05 | <0.001 | 1.05 | 1.04–1.06 | <0.001† |
Body mass index (kg/m2) | 1.01 | 0.99–1.03 | 0.211 | |||
Antiviral therapy (yes) | 1.14 | 0.94–1.37 | 0.189 | |||
Alanine aminotransferase (IU/L) | 1.00 | 0.99–1.01 | 0.604 | |||
Albumin (g/L) | 0.80 | 0.67–0.95 | 0.013 | 0.79 | 0.65–0.95 | 0.014† |
Total bilirubin (mg/dL) | 0.98 | 0.91–1.07 | 0.690 | |||
PT-INR | 0.99 | 0.93–1.06 | 0.820 | |||
Platelet count (K/mm3) | 1.00 | 0.99–1.01 | 0.116 | |||
AFP (ng/mL) | 1.00 | 0.99–1.01 | 0.431 | |||
Standardized liver volume (mL/m2) | 1.01 | 1.01–1.01 | 0.004 | 1.00 | 0.99–1.01 | 0.075 |
Standardized spleen volume ≥92.21 mL/m2 | 1.23 | 1.01–1.49 | 0.040 | 1.35 | 1.10–1.67 | 0.004† |
Skeletal muscle index (cm2/m2) | 1.00 | 0.99–1.01 | 0.686 | |||
Visceral adipose tissue index ≥28.28 cm2/m2 | 1.56 | 1.21–2.02 | 0.001 | 1.34 | 1.13–1.74 | 0.001† |
Subcutaneous adipose tissue index (cm2/m2) | 1.00 | 0.99–1.01 | 0.927 | |||
APRI | 1.00 | 0.98–1.02 | 0.932 | |||
FIB-4 | 0.99 | 0.99–1.01 | 0.571 | |||
MELD | 1.05 | 1.01–1.09 | 0.007 | 1.03 | 0.99–1.07 | 0.176 |
Characteristic |
Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Sex (female) | 0.68 | 0.46–1.01 | 0.053 | |||
Age (per 1 year) | 1.09 | 1.07–1.12 | <0.001 | 1.09 | 1.07–1.11 | <0.001† |
Body mass index (kg/m2) | 0.97 | 0.94–0.99 | 0.015 | |||
Antiviral therapy (yes) | 1.00 | 0.70–1.43 | 0.999 | |||
Alanine aminotransferase (IU/L) | 1.00 | 1.00–1.01 | 0.085 | |||
Albumin (g/L) | 0.48 | 0.40–0.58 | <0.001 | 0.51 | 0.40–0.65 | <0.001† |
Total bilirubin (mg/dL) | 1.06 | 0.99–1.15 | 0.115 | |||
PT-INR | 1.00 | 0.93–1.08 | 0.935 | |||
Platelet count (K/mm3) | 1.00 | 0.99–1.01 | 0.784 | |||
AFP (ng/mL) | 1.00 | 1.00–1.01 | 0.073 | |||
Standardized liver volume (mL/m2) | 1.00 | 0.99–1.00 | 0.737 | |||
Standardized spleen volume | 1.00 | 0.99–1.01 | 0.148 | |||
Skeletal muscle index (cm2/m2) | 0.99 | 0.98–1.01 | 0.361 | |||
Visceral adipose tissue index (cm2/m2) | 0.99 | 0.99–1.00 | 0.678 | |||
Subcutaneous adipose tissue index ≥39.08 cm2/m2 | 0.46 | 0.32–0.66 | <0.001 | 0.49 | 0.34–0.70 | <0.001† |
APRI | 1.01 | 0.99–1.03 | 0.269 | |||
FIB-4 | 1.00 | 0.99–1.01 | 0.911 | |||
MELD | 1.12 | 1.08–1.17 | <0.001 | 1.09 | 1.04–1.14 | <0.001† |
Dong Ho Lee
https://orcid.org/0000-0001-8983-851X